Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.64
-0.4000-3.07%
Post-market: 12.61-0.0335-0.27%19:59 EST
Volume:2.52M
Turnover:32.09M
Market Cap:1.46B
PE:-2.97
High:12.96
Open:12.79
Low:12.51
Close:13.04
52wk High:28.25
52wk Low:5.90
Shares:115.83M
Float Shares:102.00M
Volume Ratio:1.01
T/O Rate:2.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2519
EPS(LYR):-5.2506
ROE:-52.11%
ROA:-28.51%
PB:1.96
PE(LYR):-2.41

Loading ...

Intellia Therapeutics Inc. to Host Conference Call on Q4 and Full-Year 2025 Financial Results and Business Updates

Reuters
·
Feb 19

Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors

Simply Wall St.
·
Feb 18

Intellia Therapeutics reports inducment grants

TIPRANKS
·
Feb 06

Intellia Therapeutics Awards Inducement Grants to New Employees

Reuters
·
Feb 06

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 06

FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang

Simply Wall St.
·
Feb 04

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial

Simply Wall St.
·
Feb 01

Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis

TIPRANKS
·
Jan 31

Is Intellia Therapeutics (NTLA) Now Pricing In Too Much After Its Recent Surge

Simply Wall St.
·
Jan 29

Intellia Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 29

Intellia Therapeutics price target raised to $25 from $15 at H.C. Wainwright

TIPRANKS
·
Jan 28

Intellia Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $25 From $15

THOMSON REUTERS
·
Jan 28

Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Saftey Freeze on Nerve Disease Trial

TIPRANKS
·
Jan 27

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Opus Genetics (IRD) and Argenx Se (ARGX)

TIPRANKS
·
Jan 27

BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare

Reuters
·
Jan 27

Intellia Therapeutics Shares up 23.7% Premarket After US FDA Lifts Clinical Hold on One of Co's Gene Therapy Trials

THOMSON REUTERS
·
Jan 27

Intellia Therapeutics Says FDA Lifts Hold on Phase 3 Trial of Nexiguran Ziclumeran; Shares Rise Pre-Bell

MT Newswires Live
·
Jan 27

US FDA lifts clinical hold on Intellia’s nerve disease trail

Reuters
·
Jan 27

Intellia Therapeutics Inc: Plan to Resume Magnitude-2 Patient Enrollment and Dosing

THOMSON REUTERS
·
Jan 27

Intellia Therapeutics Announces FDA Lift of Clinical Hold on Magnitude-2 Phase 3 Clinical Trial in Attrv-Pn

THOMSON REUTERS
·
Jan 27